Abstract | BACKGROUND:
Cariprazine was approved for treating schizophrenia and bipolar disorder, and currently is being evaluated for treating depression in clinical trials in the United States. We systematically reviewed the literature on the efficacy and safety of cariprazine. METHODS: We performed a literature search of the PubMed, MEDLINE, PsycINFO, EMBASE, and Cochrane collaboration databases through August 31, 2016. The search was not restricted by patient age. Articles published in English or official English translations were included. RESULTS: CONCLUSIONS: Our review indicates that cariprazine demonstrates superior efficacy and good tolerability, both at low and high doses, in the treatment of individuals with psychosis, mania, and depression.
|
Authors | Aarti Chhatlani, Syeda Arshiya Farheen, Madhuri Jakkam Setty, Rajesh R Tampi |
Journal | Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists
(Ann Clin Psychiatry)
Vol. 30
Issue 4
Pg. 326-334
(11 2018)
ISSN: 1547-3325 [Electronic] United States |
PMID | 30372510
(Publication Type: Journal Article, Systematic Review)
|
Chemical References |
- Antipsychotic Agents
- Piperazines
- Aripiprazole
- cariprazine
- Risperidone
|
Topics |
- Antipsychotic Agents
(administration & dosage)
- Aripiprazole
(administration & dosage)
- Bipolar Disorder
(drug therapy)
- Depressive Disorder
(drug therapy)
- Humans
- Piperazines
(administration & dosage)
- Risperidone
(administration & dosage)
- Schizophrenia
(drug therapy)
|